Skip to main content

Xiidra FDA Approval History

FDA Approved: Yes (First approved July 11, 2016)
Brand name: Xiidra
Generic name: lifitegrast
Dosage form: Ophthalmic Solution
Company: Shire plc
Treatment for: Dry Eye Disease

Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease.

Development timeline for Xiidra

DateArticle
Jul 12, 2016Approval FDA Approves Xiidra (lifitegrast ophthalmic solution) for Dry Eye Disease
Feb  4, 2016U.S. FDA Acknowledges Receipt of Resubmission of Shire’s NDA for Lifitegrast for Dry Eye Disease in Adults
Jan 25, 2016Shire Resubmits New Drug Application for Lifitegrast to U.S. FDA
Oct 16, 2015Shire Receives FDA Complete Response Letter for Lifitegrast NDA and Plans to Respond with OPUS-3 Trial
Apr  9, 2015U.S. FDA Grants Priority Review to Lifitegrast NDA for the Treatment of Dry Eye Disease in Adults
Mar  2, 2015Shire Submits NDA to the FDA for Approval of Lifitegrast For Treatment of Dry Eye Disease in Adults
May 16, 2014Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults

See also

Xiidra (lifitegrast) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer